Avalo Therapeutics (AVTX) Change in Cash (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Change in Cash data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Change in Cash rose 197.42% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$99.9 million (down 769.44% YoY) and the FY2025 annual result came in at -$118.6 million, down 193.27% from the prior year.
• Change in Cash climbed to $9.2 million in Q1 2026, from -$11.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $102.8 million in Q1 2024 to a low of -$82.7 million in Q2 2025.
• A 5-year average of -$1.7 million and a median of -$9.5 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash sank 1444.51% — and 2024, when it surged 2784.25%.
• Tracing AVTX's Change in Cash over 5 years: stood at -$3.9 million in 2022, then climbed by 28.33% to -$2.8 million in 2023, then surged by 2004.7% to $52.7 million in 2024, then slumped by 121.19% to -$11.2 million in 2025, then surged by 182.57% to $9.2 million in 2026.
• The last three Change in Cash figures came in at $9.2 million (Q1 2026), -$11.2 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.